Teewinot Life Sciences Advances IP for Biosynthetic Cannabinoid Production

teewinot life sciences logo
Teewinot Life Sciences Corporation’s Subsidiary, Full Spectrum Laboratories, Ltd., Announced Today: Grant of an Important U.S. Patent with Broad Claims to Biosynthetic Production of Cannabinoids

Furthers Mission to Address Unmet Medical Needs Across the Globe

TAMPA, Fla., March 7, 2017 /PRNewswire/ — Teewinot Life Sciences Corporation, a global leader in development of cannabinoid-based pharmaceuticals and Full Spectrum Laboratories, Ltd. (FSL), a wholly owned subsidiary of Teewinot, announced today: grant of U.S. Patent No. 9,587,212 (“the ‘212 patent”) entitled Apparatus and Methods for Biosynthetic Production of Cannabinoids. The ‘212 patent has broad claims to a system for production of cannabinoids using cannabinoid biosynthetic enzymes expressed in microorganisms transformed with cannabinoid biosynthetic genes. FSL provides its cannabinoid biosynthetic services to others, and its cannabinoid biosynthesized pharmaceuticals, under its CannSynthesis™. FSL’s proprietary processes are used to manufacture kilogram quantities of a wide range of pharmaceutically pure cannabinoids such as THCA, THC, THCVA, THCV, CBDA, CBD, CBDVA, CBDV, CBCA, CBC, CBCVA, CBCV, CBGA, CBG, CBGVA, and CBGV.

Our proprietary biosynthetic processes revolutionize cannabinoid-based pharmaceutical development. The ‘212 patent claims cover genetic engineering of microorganisms with genes cloned from the Cannabis plant that code for cannabinoid biosynthetic enzymes and the use of the genetically engineered microorganisms to produce commercial quantities of pharmaceutically pure cannabinoids. The ‘212 patent is an important addition to FSL’s increasingly valuable patent portfolio.

Richard Peet TeewinotDr. Richard Peet, Teewinot’s Executive Vice President, FSL’s Managing Director, and co-inventor of the ‘212 patent

Jeffrey M. Korentur, Teewinot’s President and CEO said, “We are encouraged by the volume of inquiries coming from all over the world as our manufacturing catalog expands. This demonstrated interest in our capabilities highlights the significant need for the diversity, price, and purity of cannabinoids we produce and the formulations we can create. Cannabinoid pharmaceutical developments are accelerating, and we’re proud to play a role in this expanding field of medicine.”

Teewinot seeks partners interested in working with our company to commercialize these important cannabinoids and provide patients with new healthcare solutions.

About Teewinot Life Sciences Corporation and Full Spectrum Laboratories, Ltd.

Teewinot Life Sciences Corporation is an international biopharmaceutical company focused on advanced pharmaceutical research and the use of novel biosynthetic processes such as biocatalysis and synthetic biology for cannabinoid manufacture. Coupled with patented formulation technologies, Teewinot is a leader in the production and delivery of cannabinoid-based therapies. With headquarters in Tampa, Florida, Teewinot’s global proprietary technology and intellectual property portfolio represent a breakthrough in the manufacture and delivery of cannabinoid-based pharmaceuticals. For more information, please visit www.tlscorp.com or follow us on Twitter (@teewinot_corp). Full Spectrum Laboratories, Ltd. is a wholly owned subsidiary of Teewinot. With headquarters in Dublin, Ireland, FSL operates as the nexus of global commercial activities for the Teewinot family of companies.

Original press release: http://www.prnewswire.com/news-releases/teewinot-life-sciences-corporations-subsidiary-full-spectrum-laboratories-ltd-announced-today–grant-of-an-important-us-patent-with-broad-claims-to-biosynthetic-production-of-cannabinoids-300418618.html

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter